Movement Alert｜XTALPI Rises 5.2% in Regular Trading, Broker Maintains Buy Rating as Pharma Sector Rally Continues

Market Focus08-05

On August 5, XTALPI rose 5.2% in regular trading, trading at HKD 7.32/share, with turnover of HKD 217 million.

On the news front, Zheshang Securities published a research report on August 3 maintaining a Buy rating on XTALPI. The broker noted that after excluding the high-base effect from a one-time DoveTree pipeline BD payment in the prior-year period, the company's core business revenue reached RMB 250 million, representing 65% year-over-year growth. Notably, its AI for Science intelligent solutions segment generated over RMB 180 million in revenue, surging 120% year-over-year.

Additionally, the Hong Kong-listed healthcare sector rallied broadly on August 4, with WuXi AppTec gaining over 12% and Genscript Biotech rising over 10%. This sector momentum carried into today's session, providing further support for XTALPI's share price.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1135154533?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-08-05 13:26","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1135154533","market":"us","top_or_hot":-1,"title":"Movement Alert｜XTALPI Rises 5.2% in Regular Trading, Broker Maintains Buy Rating as Pharma Sector Rally Continues","media":"Market Focus","content":"<p><p>On August 5, XTALPI rose 5.2% in regular trading, trading at HKD 7.32/share, with turnover of HKD 217 million.</p><p>On the news front, Zheshang Securities published a research report on August 3 maintaining a Buy rating on XTALPI. The broker noted that after excluding the high-base effect from a one-time DoveTree pipeline BD payment in the prior-year period, the company's core business revenue reached RMB 250 million, representing 65% year-over-year growth. Notably, its AI for Science intelligent solutions segment generated over RMB 180 million in revenue, surging 120% year-over-year.</p><p>Additionally, the Hong Kong-listed healthcare sector rallied broadly on August 4, with WuXi AppTec gaining over 12% and Genscript Biotech rising over 10%. This sector momentum carried into today's session, providing further support for XTALPI's share price.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Movement Alert｜XTALPI Rises 5.2% in Regular Trading, Broker Maintains Buy Rating as Pharma Sector Rally Continues</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMovement Alert｜XTALPI Rises 5.2% in Regular Trading, Broker Maintains Buy Rating as Pharma Sector Rally Continues\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1054767329\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Market Focus </p>\n<p class=\"h-time\">2026-08-05 13:26</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><p>On August 5, XTALPI rose 5.2% in regular trading, trading at HKD 7.32/share, with turnover of HKD 217 million.</p><p>On the news front, Zheshang Securities published a research report on August 3 maintaining a Buy rating on XTALPI. The broker noted that after excluding the high-base effect from a one-time DoveTree pipeline BD payment in the prior-year period, the company's core business revenue reached RMB 250 million, representing 65% year-over-year growth. Notably, its AI for Science intelligent solutions segment generated over RMB 180 million in revenue, surging 120% year-over-year.</p><p>Additionally, the Hong Kong-listed healthcare sector rallied broadly on August 4, with WuXi AppTec gaining over 12% and Genscript Biotech rising over 10%. This sector momentum carried into today's session, providing further support for XTALPI's share price.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"02228","symbol_name":"晶泰控股","start_time":0,"source_url":"","article_id":"1135154533","we_media_id":"1054767329","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1135154533","pubTimestamp":1785907583,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Market Focus","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1054767329","head_image":"https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a"},"summary":"On August 5, XTALPI rose 5.2% in regular trading, trading at HKD 7.32/share, with turnover of HKD 217 million.On the news front, Zheshang Securities published a research report on August 3...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"02228":"晶泰控股"},"translate_title":"走势警报|XTALPI 在常规交易中上涨 5.2%，随着制药行业持续上涨，经纪商维持买入评级","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02228":1},"content_text":"On August 5, XTALPI rose 5.2% in regular trading, trading at HKD 7.32/share, with turnover of HKD 217 million.On the news front, Zheshang Securities published a research report on August 3 maintaining a Buy rating on XTALPI. The broker noted that after excluding the high-base effect from a one-time DoveTree pipeline BD payment in the prior-year period, the company's core business revenue reached RMB 250 million, representing 65% year-over-year growth. Notably, its AI for Science intelligent solutions segment generated over RMB 180 million in revenue, surging 120% year-over-year.Additionally, the Hong Kong-listed healthcare sector rallied broadly on August 4, with WuXi AppTec gaining over 12% and Genscript Biotech rising over 10%. This sector momentum carried into today's session, providing further support for XTALPI's share price.(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.47.1","shortVersion":"4.47.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1135154533","isCrawlerRequest":true}